In November, a fake (but Twitter Blue verified) account said Eli Lilly would make its insulin free, highlighting a situation Cory Zapatka explained in 2019 about the rising prices for something many people need to stay alive.
Now NBC News and the New York Times confirm the drugmaker has actually announced a 70 percent price cut on “its most commonly prescribed insulins,” and an expanded program to cap out-of-pocket patient costs.


